Fig 1.
*Pathologic diagnoses other than non-specific glomerulonephritis (GN), amyloidosis, crescentic GN, diabetic nephropathy, focal segmental glomerular sclerosis (FSGS), immunoglobulin (Ig)A nephropathy, lupus nephritis, minimal change lesion, membranous nephropathy, membranous proliferative GN (MPGN)-immune complex type, tubulointerstitial nephritis (TIN), or thrombotic microangiopathy (TMA).
Table 1.
Clinical characteristics of patients according to the presence of cancer at the time of kidney biopsy.
Table 2.
The types of cancer diagnosed at the time of kidney biopsy.
Table 3.
The risk of cancer incidence according to the pathologic diagnosis of kidney biopsy.
Table 4.
Observed, expected, and observed/expected ratio of cancer at the time of kidney biopsy from 2003 to 2015.
Table 5.
Observed, expected, and observed/expected ratio of cancer in each glomerulonephritis (GN) from 2003 to 2015.